Purinergic signalling - An overview

Novartis Foundation Symposium

Volumn 276, Issue , 2006, Pages 26-48

  Burnstock, Geoffrey ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ISOPROTEIN; PURINE DERIVATIVE; PURINE RECEPTOR;

ANIMAL; CHEMISTRY; CLASSIFICATION; CYTOLOGY; GENETICS; HUMAN; METABOLISM; MORPHOGENESIS; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; PURKINJE CELL; REVIEW; SIGNAL TRANSDUCTION; SKIN; SYNAPTIC TRANSMISSION; ULTRASTRUCTURE;

ANIMALS; HUMANS; MORPHOGENESIS; NEUROTRANSMITTER AGENTS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, SECONDARY; PURINES; PURKINJE CELLS; RECEPTORS, PURINERGIC; SIGNAL TRANSDUCTION; SKIN; SYNAPTIC TRANSMISSION;

EID: 33747423674     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (52)

1. Abbracchio MP 1996 P1 and P2 receptors in cell growth and differentiation. Drug Dev Res 39:393-406
2. 2Y purinoceptors? Pharmacol Ther 64:445-475
3. Abbracchio MP, Burnstock G 1998 Purinergic signalling: pathophysiological roles. Jpn J Pharmacol 78:113-145
4. Abbracchio MP, Ceruti S, Bolego C, Puglisi L, Burnstock G, Cattabeni F 1996 Trophic roles of P2-purinoceptors in central nervous system astroglial cells. In: P2 purinoceptors: localization, function and transduction mechanisms. Wiley, Chichester (Ciba Found Symp 198) p 142-148
5. 14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 24:52-55
6. Abraham EH, Salikhova AY, Rapaport E 2003 ATP in the treatment of advanced cancer. Curr Top Membr 54:415-452
7. Agteresch HJ, van Rooijen MHC, van den Berg JWO, Minderman-Voortman GJ, Wilson JHP, Dagnelie PC 2003 Growth inhibition of lung cancer cells by adenosine 5-triphosphate. Drug Dev Res 60:196-203
8. Barnard EA, Burnstock G, Webb TE 1994 G protein-coupled receptors for ATP and other nucleotides: a new receptor family. Trends Pharmacol Sci 15:67-70
9. Bodin P, Burnstock G 2001 Purinergic signalling: ATP release. Neurochem Res 26:959-969
10. Bogdanov YD, Dale L, King BF, Whittock N, Burnstock G 1997 Early expression of a novel nucleotide receptor in the neural plate of Xenopus embryos. J Biol Chem 272:12583-12590
11. Brake AJ, Wagenbach MJ, Julius D 2004 New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 371:519-523
12. Burnstock G 1972 Purinergic nerves. Pharmacol Rev 24:509-581
13. Burnstock G 1976 Do some nerve cells release more than one transmitter? Neuroscience 1:239-248
14. Burnstock G 1978 A basis for distinguishing two types of purinergic receptor. In: Straub RW, Bolis L (eds) Cell membrane receptors for drugs and hormones: A multidisciplinary approach. Raven Press, New York, p 107-118
15. Burnstock G 1996a Purinoceptors: ontogeny and phylogeny. Drug Dev Res 39:204-242
16. Burnstock G 1996b A unifying purinergic hypothesis for the initiation of pain. Lancet 347:1604-1605
17. Burnstock G 1999a Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J Anat 1954:335-342
18. Burnstock G 1999b Purinergic cotransmission. Brain Res Bull 50:355-357
19. Burnstock G 2001a Purine-mediated signalling in pain and visceral perception. Trends Pharmacol Sci 22:182-188
20. Burnstock G 2001b Purinergic signalling in development. In: Abbracchio MP, Williams M (eds) Handbook of experimental pharmacology, Vol 151/I. Purinergic and pyrimidinergic signalling I. Springer-Verlag, Berlin, p 89-127
21. Burnstock G 2002a Purinergic signalling and vascular cell proliferation and death. Arterioscl Thrombosis Vasc Biol 22:364-373
22. Burnstock G 2002b Potential therapeutic targets in the rapidly expanding field of purinergic signalling. Clin Med 2:45-53
23. Burnstock G 2004 Cotransmission. Curr Opin Pharmacol 4:47-52
24. 2-purinoceptor? Gen Pharmacol 16:433-440
25. Burnstock G, Wood JN 1996 Purinergic receptors: their role in nociception and primary afferent neurotransmission. Curr Opin Neurobiol 6:526-532
26. Burnstock G, Knight GE 2004 Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240:31-304
27. Burnstock G, Campbell G, Satchell D, Smythe A 1970 Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br J Pharmacol 40:668-688
28. Cobb BR, Clancy JP 2003 Molecular and cell biology of adenosine receptors. Curr Top Membr 54:151-181
29. Drury AN, Szent-Györgyi A 1929 The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J Physiol (Lond) 68:213-237
30. Gordon JL 1986 Extracellular ATP: effects, sources and fate. Biochem J 233:309-319
31. Greig AVH, Linge C, Terenghi G, McGrouther DA, Burnstock G 2003 Purinergic receptors are part of a functional signalling system for proliferation and differentiation of human epidermal keratinocytes. J Invest Dermatol 120:1007-1015
32. Hoebertz A, Arnett TR, Burnstock G 2003 Regulation of bone resorption and formation by purines and pyrimidines. Trends Pharmacol Sci 24:290-297
33. Hollopeter G, Jantzen H-M, Vincent D et al 2001 Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202-207
34. 2+ signalling in glial cell pathology in the central nervous system. Eur J Pharmacol 447:247-260
35. 3 homomeric and heteromeric channels to acute and chronic pain. Expert Opin Ther Targets 4:513-522
36. King BF, Burnstock G 2002 Purinergic receptors In: Pangalos M, Davies C (eds) Understanding G protein-coupled receptors and their role in the CNS. Oxford University Press, Oxford, p 422-438
37. Kunapuli SP, Ding Z, Dorsam RT, Kim S, Murugappan S, Quinton TM 2003 ADP receptors-targets for developing antithrombotic agents. Curr Pharmacol Des 9:2303-2316
38. Lammas DA, Stober C, Harvey CJ, Kendrick N, Panchalingam S, Kumararatne DS 1997 ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7) receptors. Immunity 7:433-444
39. Lazarowski ER, Boucher RC, Harden TK 2003 Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol 64:785-795
40. 1 receptors in the rat cerebellum. Cell Tissue Res 294:253-260
41. 2 receptor immunoreactivity in the rat hypothalamo-neurohypophysial system. J Neurocytol 28:495-504
42. Luttikhuizen DT, Harmsen MC, de Leij LF, van Luyn MJ 2004 Expression of P2 receptors at sites of chronic inflammation. Cell Tissue Res 317:289-298
43. Neary JT, Rathbone MP, Cattabeni F, Abbracchio MP, Burnstock G 1996 Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci 19:13-18
44. Neary JT, Kang Y, Willoughby KA, Ellis EF 2003 Activation of extracellular signal-regulated kinase by stretch-induced injury in astrocytes involves extracellular ATP and P2 purinergic receptors. J Neurosci 23:2348-2356
45. North RA 2002 Molecular physiology of P2X receptors. Physiol Rev 82:1013-1067
46. O'Connor SE, Dainty IA, Leff P 1991 Further subclassification of ATP receptors based on agonist studies. Trends Pharmacol Sci 12:137-141
47. Ralevic V, Burnstock G 1998 Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492
48. 5 receptor on satellite cells. J Cell Biol 158:345-355
49. Ryten M, Yang SY, Dunn PM, Goldspink G, Burnstock G 2004 Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures. FASEB J 18:1404-1406
50. 4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424:778-783
51. Van Calker D, Müller M, Hamprecht B 1979 Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 33:999-1005
52. Wynn G, Rong W, Xiang Z, Burnstock G 2003 Purinergic mechanisms contribute to mechanosensory transduction in the rat colorectum. Gastroenterology 125:1398-1409